Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure

Fundacion IMIM2,178 enrolled

Overview

The purpose of this study is to describe the management of patients with chronic hepatitis C and previous treatment failure.

Study Type

OBSERVATIONAL

Enrollment

2,178

Conditions

Hepatitis C

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients of both sexes older than 18 years old. * Patients with hepatitis C who had previously failed to the standard therapy. * Patients who have given written informed consent to participate in the study. Exclusion Criteria: * Patients with clinical and/or social conditions that might interfere with the development of the study (terminal diseases, cognitive detriment, severe psychiatric disease which prevent from obtaining the information required, prolonged absences during the study). * Patients who are participating in other research trials or under treatment with any agent contraindicated according to the summary of product characteristics or other circumstance which requires a patient management different from the investigator's regular clinical practice.

Locations (104)

Outcomes

Primary Outcomes

Describe the management of patients with chronic hepatitis C and previous treatment failure

Time frame: 6 years

Secondary Outcomes

To know the frequency of the causes for not responding to the previous treatment: lack of adherence to treatment, incomplete dose of antiviral treatment, insufficient treatment duration or treatment resistance.

Time frame: 6 years

To assess the percentage of patients with previous treatment failure who are not candidates for re-treatment and its causes.

Time frame: 6 years

To evaluate the implementation of current recommendations based on the cause of the previous therapeutic failure, in patients with chronic hepatitis C in whom a new course of the antiviral treatment is decided to be administered.

Time frame: 6 years

To know the causes of the dose modifications and withdrawal of treatment during the follow-up period in patients who start re-treatment.

Time frame: 6 years

To know the percentage of patients that achieve sustained viral response when implementing the recommendations based on the cause of the previous therapeutic failure.

Time frame: 6 years

To determine the presence of the polymorphism rs12979860 in the gene IL 28B located on chromosome 19.

The rs12979860 polymorphism in the gene IL 28B that is located on chromosome 19 showed to be strongly associated with the development of sustained viral response (SVR) in patients with chronic hepatitis C treated with PEG-IFN-α/RBV. Patients with this polymorphism clear the virus more easily.

Time frame: 6

Compare the management of patients with chronic hepatitis C prior treatment failure before and after the appearance of new treatments.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

H. de Antequera

Antequera, Andalusia, Spain

H. Puerta de Mar

Cadiz, Andalusia, Spain

H. Puerto Real

Cadiz, Andalusia, Spain

H. Vírgen de las Nieves

Granada, Andalusia, Spain

H. Infanta Elena

Huelva, Andalusia, Spain

H. de Jaen

Jaén, Andalusia, Spain

H. de Jerez

Jerez de la Frontera, Andalusia, Spain

H. Carlos Haya

Málaga, Andalusia, Spain

H. Vírgen de la Victoria

Málaga, Andalusia, Spain

H. de Valme

Seville, Andalusia, Spain

...and 94 more locations